Q3 EPS Estimate for Dolby Laboratories Lifted by Analyst

Dolby Laboratories logo with Technology background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research raised its Q3 2027 EPS estimate for Dolby Laboratories to $0.58 from $0.57, while maintaining a Hold rating. It also forecasts $3.20 EPS for FY2027 and $3.40 for FY2028.
  • Analyst views are mixed: Rosenblatt cut its price target to $80 from $85 but kept a Buy rating, while MarketBeat reports an overall Moderate Buy consensus and an $85 average target.
  • Dolby’s board approved a $350 million share repurchase plan, authorizing buybacks of up to 7% of the company’s stock.
  • MarketBeat previews top five stocks to own in December.

Dolby Laboratories (NYSE:DLB - Free Report) - Investment analysts at Zacks Research increased their Q3 2027 earnings per share (EPS) estimates for Dolby Laboratories in a note issued to investors on Monday, November 16th. Zacks Research analyst Team now expects that the electronics maker will post earnings per share of $0.58 for the quarter, up from their prior estimate of $0.57. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Dolby Laboratories' current full-year earnings is $3.23 per share. Zacks Research also issued estimates for Dolby Laboratories' FY2027 earnings at $3.20 EPS, Q1 2028 earnings at $0.66 EPS, Q2 2028 earnings at $0.92 EPS, Q3 2028 earnings at $0.87 EPS and FY2028 earnings at $3.40 EPS.

DLB has been the subject of a number of other research reports. Wall Street Zen lowered shares of Dolby Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Weiss Ratings upgraded shares of Dolby Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, September 9th. Finally, Rosenblatt Securities cut their target price on shares of Dolby Laboratories from $85.00 to $80.00 and set a "buy" rating on the stock in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $85.00.

Read Our Latest Report on Dolby Laboratories

Dolby Laboratories Trading Down 3.9%

NYSE:DLB opened at $61.13 on Tuesday. The stock has a market cap of $5.73 billion, a P/E ratio of 26.01 and a beta of 0.79. The stock's 50-day moving average is $60.97 and its 200-day moving average is $59.43. Dolby Laboratories has a 1-year low of $48.26 and a 1-year high of $69.95.

Hedge Funds Weigh In On Dolby Laboratories

A number of hedge funds have recently made changes to their positions in DLB. Bank of New York Mellon Corp bought a new stake in Dolby Laboratories in the second quarter valued at $253,289,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Dolby Laboratories during the third quarter valued at about $40,429,000. Advisors Asset Management Inc. bought a new position in shares of Dolby Laboratories during the 3rd quarter worth about $34,670,000. First Trust Advisors LP boosted its position in shares of Dolby Laboratories by 19.9% during the 1st quarter. First Trust Advisors LP now owns 2,254,933 shares of the electronics maker's stock worth $135,431,000 after purchasing an additional 374,405 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Dolby Laboratories during the 3rd quarter worth about $13,622,000. 58.56% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Dolby Laboratories news, CAO Ryan Nicholson sold 1,183 shares of Dolby Laboratories stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $65.28, for a total transaction of $77,226.24. Following the transaction, the chief accounting officer directly owned 34,453 shares of the company's stock, valued at approximately $2,249,091.84. The trade was a 3.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP John D. Couling sold 7,667 shares of the company's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $58.78, for a total value of $450,666.26. Following the completion of the sale, the senior vice president owned 166,803 shares in the company, valued at $9,804,680.34. This trade represents a 4.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,517 shares of company stock valued at $995,963 over the last 90 days. 37.93% of the stock is currently owned by company insiders.

Dolby Laboratories announced that its Board of Directors has approved a share repurchase plan on Thursday, July 30th that permits the company to repurchase $350 million in shares. This repurchase authorization permits the electronics maker to repurchase up to 7% of its stock through open market purchases. Share repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Dolby Laboratories News Roundup

These are some of the DLB news items that stood out recently:

  • Positive Sentiment: Zacks Research slightly raised its FY2027 and FY2028 earnings-per-share estimates to $3.20 and $3.40, respectively, and nudged up forecasts for several 2027–2028 quarters. These modest upgrades offer a favorable signal on expected earnings, though the firm maintains a Hold rating. Dolby Laboratories analyst coverage
  • Neutral Sentiment: Rosenblatt Securities lowered its price target to $80 from $85 but kept a Buy rating. The revised target still indicates substantial upside relative to the cited $61.13 share price, while the cut tempers the otherwise positive view. Rosenblatt Securities ratings
  • Neutral Sentiment: Dolby is scheduled to report quarterly results, putting the focus on its performance and outlook. The earnings-preview coverage provided no specific results or forecast that would point clearly in either direction. Dolby Laboratories earnings preview

About Dolby Laboratories

(Get Free Report)

Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.

Read More

Earnings History and Estimates for Dolby Laboratories (NYSE:DLB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dolby Laboratories Right Now?

Before you consider Dolby Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dolby Laboratories wasn't on the list.

While Dolby Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines